Figure 3 | Scientific Reports

Figure 3

From: Elexacaftor/tezacaftor/ivacaftor influences body composition in adults with cystic fibrosis: a fully automated CT-based analysis

Figure 3

Study flow diagram showing inclusion criteria and analyzed cohort. Initially, 204 people with CF (pwCF) receiving elexacaftor/tezacaftor/ivacaftor (ETI) were screened. After filtering out 40 pwCF without available chest CT scans and 98 pwCF obtaining CT scans independent of ETI therapy initiation and/or with missing follow-up CT scan, 66 pwCF remained as the final cohort.

Back to article page